SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-010888
Filing Date
2021-08-09
Accepted
2021-08-09 09:01:29
Documents
48
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ewtx-20210630x10q.htm   iXBRL 10-Q 1975486
2 EX-31.1 ewtx-20210630xex31d1.htm EX-31.1 17136
3 EX-31.2 ewtx-20210630xex31d2.htm EX-31.2 17410
4 EX-32.1 ewtx-20210630xex32d1.htm EX-32.1 11468
  Complete submission text file 0001558370-21-010888.txt   5602376

Data Files

Seq Description Document Type Size
5 EX-101.SCH ewtx-20210630.xsd EX-101.SCH 27557
6 EX-101.CAL ewtx-20210630_cal.xml EX-101.CAL 27599
7 EX-101.DEF ewtx-20210630_def.xml EX-101.DEF 123362
8 EX-101.LAB ewtx-20210630_lab.xml EX-101.LAB 296874
9 EX-101.PRE ewtx-20210630_pre.xml EX-101.PRE 222367
10 EXTRACTED XBRL INSTANCE DOCUMENT ewtx-20210630x10q_htm.xml XML 799710
Mailing Address 3415 COLORADO AVE. BOULDER CO 80303
Business Address 3415 COLORADO AVE. BOULDER CO 80303 303-735-8373
Edgewise Therapeutics, Inc. (Filer) CIK: 0001710072 (see all company filings)

IRS No.: 821725586 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40236 | Film No.: 211154823
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences